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Which Benzodiazepine, Why and How?
J. L. STRAUGHAN
SUMMARY
While no major differences with regard to psychopharma-
cological actions are to be found among the benzodiaze-
pines, certain pharmacokinetic differences are known.
These differences allow the benzodiazepines to be classi-
fied as cumulative or non-cumulative; the differences be-
tween these two groups are further dissected and
evaluated, in an attempt to rationalize therapy with these
agents.
S. Air. med. l., 55, 1110 (1979).
Rational use of drugs demands a certain mlOlIDum base
of hard data. The enquiring prescriber will hunt out
such data as he thinks pertinent and useful, but the vast
majority of prescribers require reviews to enable t~em
to obtain with relative ease and in a minimum of tlme
the essentials of the relevant information.
This review aims to draw some distinctions between
the various benzodiazepines, which hopefully may be of
value in an area of therapeutics that seems beset with
a superfluity of agents looking for conditions to treat! .
Anxiety is the most common 'dis-ease' encountered 10
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medical practice; this has ensured that pharmaceuticals
promising respite from this experience find a ready market.
For several decades the barbiturates were widely used as
sedative, anti-anxiety agents. Nothing really new was
forthcoming until about 1960, when the benzodiazepines
appeared on the pharmacotherapeutic scene.
The benzodiazepines were innovative, particularly with
regard to their safety, both in normal doses and in large
overdoses. They have several other advantages over the
barbiturates: by careful adjustment of dosage, the anti-
anxiety effect may usually be obtained with minimal
sedative effect; tolerance and dependence are less pre-
valent; and there is no significant induction of hepatic
microsomal enzymes, and thus no accelerated biotrans-
formation of endogenous substances or other exogenous
substances also metabolized by these enzymes.
Thus, it is easy to understand why this group of drugs
has become a worldwide best-seller. Nevertheless, it is
salutary to bear in mind that the therapeutic spectrum of
the benzodiazepines is not very different from that of the
barbiturates.
ARE THE BENZODIAZEPINES A
HOMOGENEOUS GROUP?
With regard to their pharmacological actions, there is very
little of major importance to differentiate the various
benzodiazepines on the market in the Republic of South
Africa. Once variations in potency and dosage have been
taken into account, these agents have remarkably similar
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pharmacodynamic properties. However, at a time when
the introduction of yet more benzodiazepines is imminent,
it is increasingly important to make some comments which
might assist in rationalizing benzodiazepine therapy, or
which might at least provoke some reassessment of their
usage.
DIFFERENCES IN METABOLISM AND
ELIMINATION
It is very largely on the basis of pharmacokinetic data that
marked differences among the benzodiazepines may be dis-
cerned and choices may be made in a more rational
manner. The pharmacokinetic properties that reflect
marked differences among the various benzodiazepines are
those of biotransformation (metabolism) and elimination.
If we examine the pharmacokinetic properties of the
benzodiazepines, it is evident that they may usefully
be divided into two classes: group 1 - short-acting, with
very little tendency to accumulate, e.g. temazepam (Levan-
xol); oxazepam (Serepax); lorazepam (Ativan) (this group
is characterized chemically by possessing a hydroxyl group
in the 3 position); and group 2 - long-acting, with a con-
siderable tendency to accumulate, e.g. diazepam (Valium);
chlordiazepoxide (Librium); chlorazepate (Tranxene);
f1urazepam (Dalmadorm); medazepam ( obrium).
In Table I some common benzodiazepines are listed and
their major active metabolites and their respective plasma
half-lives are indicated, in accordance with the above-
mentioned classifiication.
It should be noted that the biotransformation products
of the short-acting benzodiazepines are directly conjugated.
These conjugated products are essentially inactive, water-
soluble and very readily cleared by the kidneys. The
longer-acting benzodiazepines are biotransformed via a
cascade of other active products, most of which have long
plasma half-lives. The active biotransformation products
are formed sequentially to a large extent; for instance,
when diazepam is administered as a single dose, the
benzodiazepine-type effect is produced for a period related
to (inter alia) the sum of the individual plasma half-
lives of each of the active products. Fig. I illustrates
these points.
Such long duration of action makes the prescription of
these agents on a 2, 3, or 4 times-a-day basis look quite
nonsensical. From a pharmacotherapeutic viewpoint the
agents might very advantageously be administered once
a day, and several of them could well be administered
TABLE I. SOME COMMON BENZODIAZEPINES, THEIR MAJ OR ACTIVE METABOLlTES AND RESPECTIVE PLASMA
HALF-LIVES
Group 1 -
short-acting
Group 2 -
long-acting
Parent drug
jOxazepam(Serepax)Temazepam
l
(Levanxol)
Lorazepam
(Ativan)
Diazepam
(Valium)
Chlordiazepoxide
(Librium)
K-chlorazepate
(pro-drug)
(Tranxene)
Medazepam
(Nobrium)
Prazepam
(Demetrin)
Nitrazepam
(Mogadon)
Flurazepam
(Dalmadorm)
Active biotransformation
product/s
None
Oxazepam (very small amounts)
None
Desmethyldiazepam
Temazepam
Oxazep<:lnl
Desmethylchlordiazepoxide
Desmethyldiazepam
Demoxepam
Oxazepam
r)esmethyldiazepam
Oxazepam
Desmethyldiazepam
Diazepam
Desmethyldiazepam
Desmethyldiazepam
Oxazepam
? - but probable
Desalkylfurazepam
Plasma half-life"
(h)
5 - 10
6 - 8
5· 10
8- 20
20 - 90
36 - 200
6 - 8
5 - 10
5· 30
30 - 90
36 - 200
15 - 95
5 - 10
evanescentt
36 - 200
5- 10
10 - 24
40 - 100
20 - 90
36 - 200
uncertain
36 - 200
5 - 10
20 - 38
?
1 - 4
50 -100
.. Published values may vary somewhat. These values seem to represent the expected range.
t Converted by the acid pH of the stomach to desmethyldiazepam, before absorption, therefore described as a pro-drug. Preparations or
surgIcal operations that diminish gastric acidity may be expected to reduce and delay the systemic absorption of this product.'
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(A) OIAIEPAM~
, '0
:' t~ : 20 - 90 hours
I OESMETHYlDIAZEPAA~~ n*: 36 - 200 hours
~
T;~iPAA8- - - - - - -.OXAIEPAM
" ,1- hou" ,;0, 5 - 10 hou"
zepam conjugate: O'~ _.lZepam conjugate
______ u,in._________
The interval of a couple of days before oxazepam
attains steady-state conditions (when plasma levels and
elimination processes attain fair constancy with constant
dosage) is of that order because pharmacokineticists have
demonstrated that, as a general rule, steady-state con-
ditions are established after about 4 or 5 half-lives have
elapsed since initiation of therapy. Thus for oxazepam,
with a plasma half-life of approximately 10 hours, it
would require about 2 days (5 X 10 hours) to establish
steady-state conditions.
--------- ---- - -000- -- --- _
Long-Acting Benzodiazepines
(B) CHLOROIAZEPOXIOE~
no, 5 - 30 hou" \
OESHETHYlCHlOROI AZEPOXI DE~
no, 30 - 90 hou" \
OEI1OXEPAM~
t;·, IS - 95 hou" .. \
DES"'ETHYlDIAZEPAl1~
t;O, 36 - 200 hou" \
OXAZEPAM
ttalor 0<;°' 5r10 hou"
~ xazepam conjugate
~_~!:: __~ pathvays ~
urine~
-Approximate plasma half-life values
However, when a long-acting agent such as diazepam is
administered in a regular dosage of, say, 2 mg morning
and evening, and if the plasma half-life of diazepam is
40 hours, it will be about a week before diazepam has
attained steady-state conditions! The diazepam story is
in fact much more complicated, because its major meta-
bolite, desmethyldiazepam, has a much longer plasma half-
life than the parent diazepam.' With a value of, say, 100
hours for the plasma half-life of desmethyldiazepam, it
would take about a fortnight for the plasma levels of
desmethyldiazepam to reach some constancy; because the
desmethyldiazepam derives from diazepam, which itself
slowly attains a steady state over about a week, it is
apparent that desmethyldiazepam levels will attain con-
stancy only some 3 or more weeks after initiation of
diazepam therapy. Fig. 2 illustrates this relati')nship.
Fig. 1. The main biotransformation pathways of (A)
diazepam (VaJium) and (8) chlordiazepoxide (Librium).
2B21
......./ .../.,......",.....
dLuepiilIlI.
Plasma
Con'entratlon
every other day, without the occurrence of any major
fluctuations in their plasma levels! Furthermore, if it is
borne in mind that the duration of their pharmacological
action is usually appreciably longer than their plasma
half-life, it becomes all the more apparent that the agents
are prescribed at unnecessarily short intervals, and probably
in unnecessarily high daily dosages.
These long-acting agents should be prescribed in 11 once-
a-day 'before bedtime' dose; in this way the plasma level
of the parent compound reaches a peak during the night.
This should help to promote sleep, and might help to
reduce unnecessary and perhaps undesirable and excessive
daytime sedation.
STEADY-8TATE CONDITIONS,
AND THEIR IMPLICATIONS
diazepam
started
Short-Acting Benzodiazepines
When a short-acting benzodiazepine such as oxazepam
is administered in a dose of, for example, 10 mg 3 times
a day, the plasma and tissue levels of the drug attain a
fairly stable state about 2 days after initiation of the
regimen. Thus, the effects of a particular dosage soon
become evident and maximal. This set of circumstances
makes it fairly simple to adjust dosages to suit a particular
person.
Fig. 2. Graphic representation of the relationship of the
plasma levels of diazepam, and its chief metabolite
desmethyldiazepam, during the first few weeks after
initiating diazepam administration at e.g. 5 mg/d.
It should also be noted that it is the desmethyl meta-
bolite that becomes the dominant anxiolytic. It is thus
apparent' that the effects of a particular dosage regimen
with the long-acting benzodiazepines cannot be expected
to be fully evident before some considerable time has
elapsed - about 3 or 4 weeks, in the case of diazepam.
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Therefore, when it comes to making appropriate
alterations in the dosage of the long-acting benzodiaze-
pines, the situation is much more complex than with the
short-acting members. The initial dosage used with a
long-acting benzodiazepine might well be suitable for the
first week or so, but may then become quite in excess of
what is required as the parent drug and its metabolites
accumulate.
I would make so bold as to suggest that a rational
way of prescribing the long-acting benzodiazepines, such
as diazepam, would be to initiate therapy with a dosage
of 2, 5, or 10 mg diazepam (according to the immediate
needs of the patient) morning and evening for about 7
days, and then to 'back off' and halve the initial dosage
by giving a single dose in the evening for the next 2 weeks
or so. At this stage it might well be possible to dis-
continue the medication altogether; if not, the dosage
regimen should again be carefully reassessed, bearing in
mind that the effective anxiolytic dosage is often well
below the sedative dosage.
Such an approach should make it possible to arrive
at the lowest effective dosage regimen. This is the dosage
that will minimize impairment of motor and cognitive
processes, and produce the best psychotherapeutic results,
at the least financial cost to the patient.
This type of approach takes cognizance of the peculiar
pharmacokinetics of the long-acting benzodiazepines, and
makes it possible to individualize dosages by making ad-
justments at appropriate intervals.
In the elderly, who do not eliminate the long-acting
benzodiazepines as readily as younger people, this approach
is oarticularly to be advocated, so as to avoid unnecessary
over-sedation, with all its repercussions, in the age group
that is most inclined to develop such problems.
The accumulation of the long-acting benzodiazepines,
while oerhaos subtle in most everyday circumstances. is
verv dramatically evident when diazepam is used in high
and frenuent dosage, as in the management of tetanus
oatients.' Tn these cases diazepam and its chief meta-
bolite accumulate very markedly. so that days after muscle
relaxation is no longer required the patient is still coma-
tose or stuporous, because doses too high and too frequent
have been administered for too long. Bearing in mind the
oharmacokinetic data oresented above, it should be pos-
sible to solve this prolonged recovery problem.
When fine control of dose-effect relationship is desirable,
the short-acting benzodiazepines have a decided advantage
over the longer-acting members of this drug family. In
the light of the foregoing, prescribers should familiarize
themselves with all the pertinent data about one or two
representatives from each of the two groups of benzo-
diazepines.
HYPNOTICS
With regard to the use of benzodiazepines as hypnotics,
I can find no oharmacological justification for singling out
nitrazeoam (Mogadon) and flurazepam (Dalmadorm) as
hypnotics, i.e. as 'sleeping tablets'! No data of which I
am aware suggest that these two products should be
marketed specifically for this role.
Indeed, I would express the opinion that there are two
other agents, temazepam (Levanxol) and oxazepam (Sere-
pax), that should be considered as benzodiazepines of
choice for 'sleeping tablets'. (perhaps lorazepam (Ativan),
another 3-hydroxybenzodiazepine, should also be included
in this category?) As hypnotics these agents cause fewer
'hangover' effects, for they do not tend to accumulate.
The conjugation process of oxazepam and lorazepam in
the elderly, even in the presence of hepatic dysfunction,
is not prolonged:" This might be expected to apply to
the other short-acting benzodiazepine, temazepam. Ac-
cumulation of the benzodiazepines in elderly people is
a particular hazard. Elderly people metabolize and/or
eliminate the long-acting benzodiazepines more slowly than
younger persons, and, in any case, are more prone to fall
and be unsteady on their legs; thus, long-acting benzo-
diazepines are esoecially liable to cause confusion, lethargy,
drowsiness, weakness and unsteady gait in elderly folk,
if the cumulative propensity is not taken fully into con-
sideration.
Lorazepam, despite the ease with which it can be con-
jugated and eliminated, does have a longer duration of
action than either oxazepam or temazepam (see Table I).
The halogen in lorazepam confers greater milligram-
potency, presumably as a result of better oenetration of
the central nervous system, so longer pharmacological
action might also be expected_ At the doses in which it
is available and prescribed, lorazepam is also more sedative
than either oxazeoam or temazepam, and would thus
be very useful when overt sedation is desirable, a01
accumulation remains undesirable.
On the basis of such data. I would suggest that from
among the benzodiazepines the short-acting members -
temazepam and oxazepam, and probably lorazepam -
seem to be ideally suited for prescription as hyonotics.
When an extended daytime anti-anxiety effect is re-
quired. the non-cumulative agents may be prescribed
2 - 4 times a day. Unless there are reasons such as old
age and/or hepatic disease, it would seem more rational
to prescribe one of the long-acting benzodiazepines on a
simole 'before bedtime' regimen, thus making multiple
daily dosing unnecessary.
ADVERSE WITHDRAWAL EFFECTS
The opinion seems to be fairly prevalent that lorazepam
gives rise to more dependence or 'addiction' than the
other benzodiazepines. I shall try to indicate why this
opinion might be prevalent. Because of its considerable
sedative action (at the dosages usually employed), loraze-
pam is frequently prescribed for those persons whose
anxiety levels are high. and who are then the very candi-
dates to feel anti-anxiety agent withdrawal effects more
acutely and extensively than less neurotic or less anxious
persons. Additionally. because lorazepam has no tendency
to accumulate. on abrupt withdrawal of the drug there is
a sudden decline of plasma and tissue levels (such as is
experienced. for example. with ethanol). Thus. if a person
has been receiving lorazepam for any length of time
and is 'dependent' on the drug for its anti-anxiety effective-
ness, abrupt withdrawal must. on pharmacological grounds,
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be expected to give rise to withdrawal problems. J itteriness,
jumpiness, shakiness, sweating, disturbed sleep, 'full head',
etc., have been described. Rebound anxiety and rebound
insomnia, occurring upon withdrawal, are very real entities,
therefore people receiving lorazepam or any other short-
acting benzodiazepine for periods longer than a few days
should probably have the drug withdrawn, with step-
wise reductions, over a week or more.
Group 2 benzodiazepines do not give rise to notable
withdrawal effects because of their long duration of action,
their cumulative tendency and the biotransformation
'cascade' of active products; all these militate against
sudden lowering of plasma and tissue levels of anti-anxiety
substances. Nevertheless, even when administration of
these agents is abruptly stopped there might be some mild
withdrawal symptoms and signs, such as described above.
Gradual reduction in dosage might thus also be advisable
with long-acting agents, particularly for those whose
personalities and / or disorders make this desirable.
PARENTERAL BENZODIAZEPINES
Chlordiazepoxide, diazepam and c10nazepam (Rivotril)
are available in forms suitable for intravenous admini-
stration. This gives them a special place in the emergency
or critical (for whatever reason) situation. They are
useful in many situations, e.g. in the management of con-
vulsions, ethanol withdrawal or acute anxiety 'crisis'. It
would be remiss not to mention that the intramuscular
route for the administration of these benzodiazepines is
most unsatisfactory; absorption, and therefore onset of
action after intramuscular administration (which is painful)
is known to be erratic, and also slower than that obtained
after oral ingestion! '.' The intravenous route is the route
of choice, should a rapid, incisive effect be desired. The
duration of action of single intravenous doses of diaze-
pam is short, because rapid and extensive redistribution of
the agent within the body occurs.
BUCCAL ADMINISTRATION
It is being reported that sublingual or buccal administration
of the benzodiazepines might be expected to produce
effects less rapidly than intravenous administration, but
more rapidly than oral ingestion. Several of the tablet
preparations available are suitable for administration via
the buccal route, the tablet being allowed to disintegrate
in the mouth.
An advantage of the buccal route is that the partial
but immediate breakdown of the ingested benzodiazepine
within the gastro-intestinal tract and in the liver after
absorption (first-pass effect), is bypassed, and thus more
of the parent drug is available for a more rapid onset
of effect in the central nervous system. Perhaps more
attention should be given to the formulation of tablets
suitable for administration via this route?
OTHER PARENTERAL BENZODIAZEPINES
It has also been opined that there is a niche in the benzo-
diazepine market for a parenteral form of a non-cumu-
lative agent. Such a product might be especially useful
as a sedative for minor surgical procedures, for the manage-
ment of delirium tremens and less severe alcohol with-
drawal states, and for anxiety crises. A parenteral form
of lorazepam has been investigated, and in view of -its
reported prompt efficacy via the intramuscular route;
might be a useful addition to the therapeutic range. "
NEW BENZODIAZEPINES
There are already more than a dozen different benzo-
diazepines available in South Africa. Various new benzo-
diazepines and closely related agents are champing at the
bit, waiting to be released! If these agents are truly in-
novative, pharmacodynamically, they might be welcomed;
if not, let the cry go out: 'Enough! Enough!'
CONCLUSION
Because the benzodiazepines enjoy very wide use, they
deserve to be explained in better detail to, and understood
in greater depth by medical practitioners. I believe that
the pharmaceutical firms that market these products have
promoted them as though they are not a pharmacody-
namically homogeneous group of agents, and have there-
fore not concentrated on the pharmacokinetic differences
(the real differences). It is hoped that the data and ideas
presented here might assist the medical practitioner when
prescribing benzodiazepines, or might at least provoke
some reassessment of prescribing patterns.
ADDENDUM
Since this article was prepared, there has appeared on
the South African market a new benzodiazepine derivative,
triazolam (Halcion). This triazolobenzodiazepine has a
plasma half-life of the order of 3 hours, and has no
highly active metabolites. It must therefore be ranked
among the short-acting benzodiazepines and is very suit-
able as a hypnotic.]·
I express my gratitude to colleagues in the Department of
Pharmacology for their constructive" criticism, and also to the
Merck Foundation, as it was durine the tenne of a Merck
International Fellowship in Clinical PharmLcology in the
USA that my interest in the benzodiazepines was nurtured.
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